Mito Therapies is a Colombian company founded in 2017, with a presence in several Latin American countries. It is a pioneer in the development, production, distribution, and implementation of products with high-quality standards, state-of-the-art technology, and extensive experience in the areas of inborn errors in metabolism and refractory epilepsy (resistant to antiepileptic drugs).